Clinical Trials Insight: 700020519
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2010
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 05 Jun 2010 Nilotinib is effective regardless of BCR-ABL transcript type, according to an abstract presented at ASCO 2010.
- 30 May 2008 Updated results for accelerated phase patients reported at ASCO 2008 (1113738)
- 24 Jan 2007 New trial record.